Journal of Clinical and Experimental Hematopathology最新文献_第4页

A lymph node lesion of hyper IL-6 syndrome mimicking plasmacytoma, IgG4-related disease, and Castleman disease.

IF 0.9

Journal of Clinical and Experimental Hematopathology Pub Date : 2024-01-01 DOI: 10.3960/jslrt.24039

Kenta Matsui, Hiroshi Imai, Toshiaki Kobayashi, Minoru Mizutani, Midori Filiz Nishimura, Yasuharu Sato, Kennosuke Karube, Manato Okada, Miki Usui, Keiki Kawakami, Tetsuya Murata

引用次数: 0

CD30- and CD56-positive atypical intravascular lymphocytes of the uterine cervix, mimicking intravascular lymphoma: A case report and review of the literature.

IF 0.9

Journal of Clinical and Experimental Hematopathology Pub Date : 2024-01-01 DOI: 10.3960/jslrt.24058

Daisuke Yamashita, Munemichi Otani, Hayato Maruoka, Takuya Aoki, Shigeo Hara

引用次数: 0

Epstein-Barr virus-positive plasmacytoma in an immunocompetent female: A case report. 一名免疫功能正常女性的 Epstein-Barr 病毒阳性浆细胞瘤：病例报告。

IF 0.9

Journal of Clinical and Experimental Hematopathology Pub Date : 2024-01-01 DOI: 10.3960/jslrt.24038

Hiyo Okuno, Motoha Miura, Naoki Oishi, Megumi Koshiishi-Yamada, Fumihiko Tanioka, Keita Kirito, Tetsuo Kondo

{"title":"Epstein-Barr virus-positive plasmacytoma in an immunocompetent female: A case report.","authors":"Hiyo Okuno, Motoha Miura, Naoki Oishi, Megumi Koshiishi-Yamada, Fumihiko Tanioka, Keita Kirito, Tetsuo Kondo","doi":"10.3960/jslrt.24038","DOIUrl":"10.3960/jslrt.24038","url":null,"abstract":"Plasmacytoma is defined as a plasma cell neoplasm forming a solitary osseous or extramedullary tumor without evidence of myeloma or organ damage related to a plasma cell neoplasm. Epstein-Barr virus (EBV) is associated with various B-cell neoplasms, particularly in patients with immune dysregulation; however, plasmacytoma is typically negative for EBV. Here, a case of EBV-positive sternal plasmacytoma in an immunocompetent female is presented. A 76-year-old female with no immunodeficiency presented with a tumor on the anterior thoracic wall. Imaging analysis revealed a 6.3 cm-sized tumor at the manubrium, and a needle biopsy was performed. The tumor in the bone was composed of a diffuse proliferation of plasmacytes with eccentric nuclei and a perinuclear halo. By immunohistochemistry and in situ hybridization, tumor cells were CD20-, CD3-, CD138+, κ+, λ-, EBER+, and the Ki67-labeling index was approximately 20%. Subsequent studies identified IgG κ monoclonal protein in serum but no evidence of plasma cell neoplasm-related organ damage, such as hypercalcemia, anemia, or renal dysfunction. No plasma cell neoplasm was detected in the bone marrow in the morphological and flowcytometric studies. Accordingly, the diagnosis was EBV-positive plasmacytoma. The patient was treated with local radiation therapy and achieved complete remission. EBV-positive plasmacytoma is rare in immunocompetent patients and should be carefully distinguished from plasmablastic lymphoma, another EBV-positive neoplasm with a plasma cell phenotype and an aggressive clinical course. This case also raises an important question: \"when to perform EBER in situ hybridization in diagnosing plasma cell neoplasm?\", which prompts further large case-series studies.","PeriodicalId":45936,"journal":{"name":"Journal of Clinical and Experimental Hematopathology","volume":"64 3","pages":"268-272"},"PeriodicalIF":0.9,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11528257/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142356093","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Anticancer immune reaction and lymph node sinus macrophages: a review from human and animal studies. 抗癌免疫反应和淋巴结窦巨噬细胞：人类和动物研究综述。

IF 0.9

Journal of Clinical and Experimental Hematopathology Pub Date : 2024-01-01 DOI: 10.3960/jslrt.24017

Yukio Fujiwara, Hiromu Yano, Cheng Pan, Takuya Shiota, Yoshihiro Komohara

引用次数: 0

Atypical lymphoplasmacytic and immunoblastic proliferation: A Systematic Review. 非典型淋巴浆细胞和免疫母细胞增生：系统综述。

IF 0.9

Journal of Clinical and Experimental Hematopathology Pub Date : 2024-01-01 DOI: 10.3960/jslrt.24007

Midori Filiz Nishimura, Toshiaki Takahashi, Kensuke Takaoka, Sharina Macapagal, Chalothorn Wannaphut, Asami Nishikori, Hiroko Toda, Yoshito Nishimura, Yasuharu Sato

{"title":"Atypical lymphoplasmacytic and immunoblastic proliferation: A Systematic Review.","authors":"Midori Filiz Nishimura, Toshiaki Takahashi, Kensuke Takaoka, Sharina Macapagal, Chalothorn Wannaphut, Asami Nishikori, Hiroko Toda, Yoshito Nishimura, Yasuharu Sato","doi":"10.3960/jslrt.24007","DOIUrl":"10.3960/jslrt.24007","url":null,"abstract":"Atypical lymphoplasmacytic and immunoblastic proliferation (ALPIBP) was first reported in 1984 as characteristic histological findings in lymph nodes associated with autoimmune diseases, but it has not been clearly defined to date. To summarize the histological characteristics and clinical diagnoses associated with ALPIBP, we searched MEDLINE and EMBASE for all peer-reviewed articles using keywords including \"atypical lymphoplasmacytic and immunoblastic lymphadenopathy\" from their inception to December 27, 2023. We also summarized the courses of three cases with a pathological diagnosis of ALPIBP. Nine articles with 52 cases were included. Among the total of 55 cases, including the three from our institution, the median age of the cases was 63.5 years with a female predominance (69.5%). Lymphadenopathy was generalized in 65.6% and regional in 34.4% of cases. RA (24.4%), SLE (24.4%), and autoimmune hemolytic anemia (20.0%), were common clinical diagnoses. A combination of cytotoxic chemotherapy was used in 15.6% of cases due to the suspicion of malignancy. Nodal T-follicular helper cell lymphoma, angioimmunoblastic type, methotrexate-associated lymphoproliferative disorders, and IgG4-related diseases were listed as important diseases that need to be pathologically differentiated from ALPIBP. This review summarizes the current understanding of the characteristics of ALPIBP. Given that underrecognition of ALPIBP could lead to overdiagnosis of hematological malignancy and unnecessary treatment, increased awareness of the condition in pathologists and clinicians is crucial.","PeriodicalId":45936,"journal":{"name":"Journal of Clinical and Experimental Hematopathology","volume":"64 2","pages":"97-106"},"PeriodicalIF":0.9,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11303958/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141459902","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Complex karyotype determined using conventional cytogenetic analysis is a poor prognostic factor in patients with multiple myeloma. 通过传统细胞遗传学分析确定的复杂核型是多发性骨髓瘤患者预后不良的一个因素。

IF 1.5

Journal of Clinical and Experimental Hematopathology Pub Date : 2024-01-01 DOI: 10.3960/jslrt.23047

Hideki Uryu, Yuko Mishima, Yuko Ishihara, Yuko Shirouchi, Nobuhiko Yamauchi, Mitsuhito Hirano, Kei Hirano, Yukako Teramoto, Kikuaki Yoshida, Dai Maruyama

{"title":"Complex karyotype determined using conventional cytogenetic analysis is a poor prognostic factor in patients with multiple myeloma.","authors":"Hideki Uryu, Yuko Mishima, Yuko Ishihara, Yuko Shirouchi, Nobuhiko Yamauchi, Mitsuhito Hirano, Kei Hirano, Yukako Teramoto, Kikuaki Yoshida, Dai Maruyama","doi":"10.3960/jslrt.23047","DOIUrl":"10.3960/jslrt.23047","url":null,"abstract":"High-risk cytogenetic abnormalities (HRCAs) influence the prognosis of multiple myeloma (MM). However, additional cytogenetic aberrations can lead to poor outcomes. This study aimed to clarify whether HRCAs and additional chromosomal abnormalities affect MM prognosis. Patients with newly diagnosed MM who were treated with novel agents were retrospectively evaluated. The primary objective was to assess the difference in progression-free survival (PFS) and overall survival (OS) between patients with/without HRCAs and between patients with/without complex karyotype (CK). The secondary objectives were to identify factors affecting PFS/OS and factors related to CK. HRCAs were defined as del(17p), t(4;14), t(14;16), and gain/amplification(1q) assessed using fluorescence in situ hybridization. CK was defined as ≥3 chromosomal abnormalities on G-banding. Among 110 patients, 40 had HRCAs and 15 had CK. In this study, survival durations between patients with/without HRCAs were similar, while the CK group had significantly poorer PFS/OS than the no-CK group (median PFS: 9 vs. 24 months and median OS: 29 vs. 97 months, respectively), and a poor prognostic impact of CK was maintained in patients with HRCAs. In multivariate analysis, CK was correlated with poor PFS/OS (hazard ratio [HR]: 2.39, 95% confidence interval [95% CI]: 1.22-4.66 and HR: 2.66, 95% CI: 1.10-6.45, respectively). Bone marrow plasma cell (BMPC) ≥60% (odds ratio [OR] = 6.40, 95% CI: 1.50-27.2) and Revised International Staging System III (OR = 7.53, 95% CI: 2.09-27.1) were associated with CK. Our study suggests that CK may contribute to the poor prognosis of MM. Aggressive disease status including high BMPC proliferation could be relevant to CK.","PeriodicalId":45936,"journal":{"name":"Journal of Clinical and Experimental Hematopathology","volume":"64 1","pages":"10-20"},"PeriodicalIF":1.5,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11079984/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140307301","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Histiocytic neoplasms: a brief review and differential diagnosis. 组织细胞肿瘤：简要回顾与鉴别诊断。

IF 0.9

Journal of Clinical and Experimental Hematopathology Pub Date : 2024-01-01 DOI: 10.3960/jslrt.24031

Rin Yamada, Yoshihiro Komohara

引用次数: 0

TTMV::RARA-positive acute promyelocytic leukemia with marrow necrosis and central nervous system involvement at disease recurrence. TTMV::RARA阳性急性早幼粒细胞白血病复发时伴有骨髓坏死和中枢神经系统受累。

IF 0.9

Journal of Clinical and Experimental Hematopathology Pub Date : 2024-01-01 DOI: 10.3960/jslrt.24015

Zhao Wang, Jiaqi Chen, Juanxia Meng, Mingfeng Zhao, Hongxing Liu, Xia Xiao

引用次数: 0

Salivary gland swelling as a characteristic manifestation of local cytokine release syndrome after anti-CD19 chimeric antigen receptor T cell therapy: A case series. 唾液腺肿胀是抗 CD19 嵌合抗原受体 T 细胞治疗后局部细胞因子释放综合征的特征性表现：病例系列。

IF 0.9

Journal of Clinical and Experimental Hematopathology Pub Date : 2024-01-01 DOI: 10.3960/jslrt.24035

Saki Kawase, Masatoshi Sakurai, Kyoko Masuda, Yusuke Kubota, Takahide Shindo, Ami Inokuchi, Hiroyoshi Hayashi, Misa Nakayasu, Yuka Shiozawa, Tomohiro Hirai, Takahiro Inoue, Takayuki Fujii, Haryoon Kim, Yuya Koda, Jun Kato, Keisuke Kataoka

{"title":"Salivary gland swelling as a characteristic manifestation of local cytokine release syndrome after anti-CD19 chimeric antigen receptor T cell therapy: A case series.","authors":"Saki Kawase, Masatoshi Sakurai, Kyoko Masuda, Yusuke Kubota, Takahide Shindo, Ami Inokuchi, Hiroyoshi Hayashi, Misa Nakayasu, Yuka Shiozawa, Tomohiro Hirai, Takahiro Inoue, Takayuki Fujii, Haryoon Kim, Yuya Koda, Jun Kato, Keisuke Kataoka","doi":"10.3960/jslrt.24035","DOIUrl":"10.3960/jslrt.24035","url":null,"abstract":"Cytokine release syndrome (CRS) is the most common adverse event of chimeric antigen receptor T (CAR-T) cell therapy and is usually characterized by systemic symptoms such as fever, hypotension, and hypoxia. However, there have been several recent reports of local CRS characterized by cervical swelling. This localized syndrome can cause life-threatening laryngeal edema and requires early diagnostic treatment. Here we report 3 cases of local CRS where bilateral salivary gland swelling emerged following anti-CD19 CAR-T cell therapy for relapsed or refractory diffuse large B-cell lymphoma. Following tocilizumab treatment for systemic CRS, all patients exhibited cervical swelling. Physical examinations revealed significant swelling of the bilateral submandibular glands, and computed tomography scans showed substantial enlargement of the bilateral parotid and submandibular glands. Immediate treatment with dexamethasone effectively managed the potentially life-threatening laryngeal or pharyngeal edema, thereby preventing severe airway obstruction. This study has demonstrated, for the first time to our knowledge, that salivary gland enlargement is a common finding in local CRS. This observation suggests that physicians should continue to closely monitor the risk of developing cervical edema leading to life-threatening airway obstruction after systemic CRS, even in patients treated with tocilizumab. If salivary gland swelling is observed, it would be better to consider prompt evaluation and dexamethasone administration.","PeriodicalId":45936,"journal":{"name":"Journal of Clinical and Experimental Hematopathology","volume":"64 3","pages":"261-267"},"PeriodicalIF":0.9,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11528259/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142356096","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Real-world outcomes of venetoclax and rituximab for chronic lymphocytic leukemia/small lymphocytic lymphoma: A retrospective analysis of nine Japanese cases. Venetoclax 和利妥昔单抗治疗慢性淋巴细胞白血病/小淋巴细胞淋巴瘤的实际效果：九例日本病例的回顾性分析。

IF 0.9

Journal of Clinical and Experimental Hematopathology Pub Date : 2024-01-01 DOI: 10.3960/jslrt.24014

Masuho Saburi, Takumi Nishikawa, Yasuhiko Miyazaki, Kazuhiro Kohno, Masanori Sakata, Kazuki Okuhiro, Toshiyuki Nakayama, Eiichi Ohtsuka, Masao Ogata

引用次数: 0